Matches 1 - 50 out of 310 1 2 3 4 5 6 7 >


Match Document Document Title
US20150209353 APPLICATION OF 5-HT6 RECEPTOR ANTAGONISTS FOR THE ALLEVIATION OF COGNITIVE DEFICITS OF DOWN SYNDROME  
Methods for treating Down syndrome and improving cognitive function of a patient with an intellectual disability are disclosed. 5-hydroxytryptamine sub-receptor six (5-HT6) receptor antagonists...
US20130210829 APPLICATION OF 5-HT6 RECEPTOR ANTAGONISTS FOR THE ALLEVIATION OF COGNITIVE DEFICITS OF DOWN SYNDROME  
Methods for treating Down syndrome and improving cognitive function of a patient with an intellectual disability are disclosed. 5-hydroxytryptamine sub-receptor six (5-HT6) receptor antagonists...
US20150093441 ORAL SOLID PREPARATION COMPRISING ARIPIPRAZOLE AND METHOD FOR PRODUCING ORAL SOLID PREPARATION COMPRISING ARIPIPRAZOLE  
An object of the present invention is to provide an oral solid preparation that can be produced in a simpler manner than conventional methods, that exhibits high bioavailability and high...
US20140107130 Oral Solution Formulations of Aripiprazole  
Oral solution formulations of aripiprazole, methods of manufacture of these formulations, methods of administration, and kits containing same.
US20130236573 ESKETAMINE FOR THE TREATMENT OF TREATMENT-REFRACTORY OR TREATMENT-RESISTANT DEPRESSION  
The present invention is directed to methods for the treatment of treatment-refractory depression or treatment-resistant depression comprising administering to a patient in need thereof, a...
US20150231076 ORAL SOLID PREPARATION COMPRISING ARIPIPRAZOLE AND METHOD FOR PRODUCING ORAL SOLID PREPARATION COMPRISING ARIPIPRAZOLE  
[Object] An object of the present invention is to provide an oral solid preparation that can be produced in a simpler manner than conventional methods, that exhibits high bioavailability and high...
US20140322334 ORAL SOLID PREPARATION COMPRISING ARIPIPRAZOLE AND METHOD FOR PRODUCING ORAL SOLID PREPARATION COMPRISING ARIPIPRAZOLE  
[Object] An object of the present invention is to provide an oral solid preparation that can be produced in a simpler manner than conventional methods, that exhibits high bioavailability and high...
US20150119383 ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME  
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other...
US20130245004 ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME  
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other...
US20130143867 ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME  
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other...
US20150218652 METHODS FOR DIAGNOSIS AND TREATMENT OF CANCER  
Disclosed are markers, methods and assay systems for the identification of patients suspected of having lung cancer and/or cancer patients who are predicted to respond, or not respond to the...
US20150024056 CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD  
A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle thereof, which upon constitution with...
US20140018369 CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD  
A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with...
US20120100190 CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD  
A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with...
US20150031677 TRIOXANE THIOACETAL MONOMERS AND DIMERS AND METHODS OF USE THEREOF  
Monomeric and dimeric trioxane thioacetals and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic...
US20140349999 METHODS FOR TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN  
The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present...
US20120077800 Methods for Treating Antipsychotic-Induced Weight Gain  
The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present...
US20130344146 DRY FORMULATIONS OF ARIPIPRAZOLE  
The invention encompasses dry compression pharmaceutical compositions of aripiprazole, methods of making tablets from the compositions, and tablets of the dry compression pharmaceutical composition.
US20150031655 COMBINATION OF LIVER X RECEPTOR MODULATOR AND ESTROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF AGE-RELATED DISEASES  
The disclosure provides a method of treating a mammal afflicted with an age-related disorder, comprising administering to the mammal a combination of liver X receptor (LXR) modulator and estrogen...
US20110065718 Antifungal Product, Use and Formulation Thereof  
An antifungal product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antifungal product being reached in less than about twelve...
US20150247847 DIAGNOSTIC METHOD FOR DETECTING AN AUTOIMMUNE DISEASE AND RELATED SUBJECT-MATTER  
The present invention relates to a polypeptide or protein for use in a method of diagnosis or treatment of an autoimmune disease in a subject, characterized in that said polypeptide or protein...
US20140206667 METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA  
The invention relates to methods and compositions for treating schizophrenia or bipolar disorder (in particular, mania) by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and...
US20130296337 FLASHMELT ORAL DOSAGE FORMULATION  
There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination...
US20110217342 FLASHMELT ORAL DOSAGE FORMULATION  
There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination...
US20140121193 METHODS FOR TREATING FIBROMYALGIA  
The invention provides methods for treating or ameliorating cognitive dysfunction, fatigue, energy, concentration, mood, and pain associated with fibromyalgia using compositions containing...
US20120172373 METHOD OF TREATING COGNITIVE IMPAIRMENTS AND SCHIZOPHRENIAS  
The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT1A receptor subtype, comprising as an active ingredient...
US20120214820 ORALLY DISINTEGRATING PHARMACEUTICAL DOSAGE FORM CONTAINING ARIPIPRAZOLE  
The present invention relates to an orally disintegrating dosage form containing aripiprazole. The formulation of the invention shows a fast disintegration.
US20100310681 Modulation of KCNQ Potassium Channel Activity for Treatment of Psychiatric Disorders and the Symptoms Thereof  
Disclosed herein are compositions and methods for treating a psychiatric disorder or symptoms thereof in a patient. The compositions comprise a compound that modulates KCNQ (Kv7) potassium channel...
US20130053341 THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE  
Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP) are de-scribed herein. Exemplary disorders include schizophrenia and cognitive deficit.
US20120289515 Combination therapy for cognitive distortions, resisting relapse of unipolar non-psychotic depression  
The present invention relates to a new method of treatment for persons meeting diagnoses for major depressive disorder, or other unipolar (non-bipolar, non-psychotic and non-treatment resistant)...
US20150252112 Methods for treating and/or limiting development of diabetes  
The present invention provides methods for identifying candidate compounds for limiting development of and/or treating diabetes, and methods for limiting development of and/or treating diabetes.
US20110123626 PULMONARY DELIVERY OF A FLUOROQUINOLONE  
A composition for pulmonary administration comprises a fluoroquinolone betaine, such as ciprofloxacin betaine, and an excipient. In one version, the particles have a mass median aerodynamic...
US20110160223 NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders  
Provided are pharmaceutical compositions and methods of treatment or prophylaxis of certain neuropsychiatric conditions, in particular mood disorders. The compounds are of the general Formula I-V...
US20140163039 PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS  
The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including...
US20130158044 PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS  
The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including...
US20110152286 PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS  
The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including...
US20100297181 AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ  
The invention provides methods for treating epilepsy, mental disorders and/or deficits in sensory organ by administering to patients therapeutically effective amounts of AMPA receptor antagonists...
US20140024638 TREATMENT OF COGNITIVE DYSFUNCTION IN SCHIZOPHRENIA  
The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3- yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof, pharmaceutical...
US20150231126 COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS  
Combinations of 5-HT2A inverse agonists or antagonists such as pimavanserin with antipsychotics such as risperidone are shown induce a rapid onset of antipsychotic action and increase the...
US20140234417 TABLET COMPRISING 7-[4-(4-BENZO[B]THIOPHEN-4-YL-PIPERAZIN-1-YL)BUTOXY]-1H-QUINOLIN-2-ONE OR A SALT THEREOF  
This invention relates to a tablet containing, as an active ingredient, 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quin olin-2-one or a salt thereof, that has excellent disintegration...
US20150031703 NOVEL FGFR3 FUSION  
[Problem] The present invention aims to elucidate a polynucleotide as a novel responsible gene for cancer and aims to thus provide a method for detecting the polynucleotide and a polypeptide...
US20130045981 ARIPIPRAZOLE COMPLEX FORMULATION AND METHOD  
An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin...
US20150246056 METHODS FOR TREATING OR PREVENTING SYMPTOMS OF HORMONAL VARIATIONS  
A method for treating or preventing symptoms of hormonal variation includes administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal...
US20150164906 COMPOUNDS AND METHODS OF USE THEREOF FOR TREATING NEURODEGENERATIVE DISORDERS  
Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed.
US20150111870 QUINOLINYL MODULATORS OF RORyt  
The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or...
US20130281436 DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA  
The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous...
US20140112993 FREEZE-DRIED ARIPIPRAZOLE FORMULATION  
An object of the present invention is to provide a freeze-dried aripiprazole powder formulation that exhibits good dispersibility and is easily dispersed into a homogenous suspension when...
US20140194409 Method of administration of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia  
The present invention relates to 4-((1R,3S)-6-chloro-3-phenyl-indan-1yl)-1,2,2-trimethyl-pipe razine and the salts thereof with activity at dopamine D1 and D2 receptors as well as the serotonin...
US20140018349 Dosage Regimen, Medication Dispensing Package and Uses Thereof for the Treatment of Major Depressive Disorder  
This invention provides an oral dosage regimen for the treatment of depression, a pharmaceutically acceptable medication dispensing package containing multiple dosage units of medicaments...
US20070142396 Treatment of pain with 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2(1H)-quinolone or salt thereof  
Therapeutic methods are provided for treating pain and fibromyalgia by administration of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4 -dihydro-2(1H)-quinolone or a prodrug or salt...

Matches 1 - 50 out of 310 1 2 3 4 5 6 7 >